3.45 0.07 (2.07%) | 09-22 00:00 | |||||||||||||
|
|
Short term | ||||
Mid term | ||||
Targets | 6-month : | 1-year : | ||
Resists | First : | Second : | ||
Pivot price | ||||
Supports | First : | Second : | ||
MAs | MA(5) : | MA(20) : | ||
MA(100) : | MA(250) : | |||
MACD | MACD : | Signal : | ||
%K %D | K(14,3) : | D(3) : | ||
RSI | RSI(14): | |||
52-week | High : | Low : |
If tomorrow: | Open lower | Open higher |
High: | - | - |
Low: | - | - |
Close: | - | - |
AzurRx BioPharma, Inc. engages in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal disorders. The company is headquartered in Brooklyn, New York and currently employs 12 full-time employees. The firm is engaged in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal (GI) disorders. The firm's product pipeline consists of two therapeutic proteins, such as MS1819 and AZX1101. MS1819 is an acid-resistant secreted lipase produced by Yarrowia lipolytica, known as LIP2, that the Company is developing through recombinant deoxyribonucleic acid (DNA) technology for the treatment of exocrine pancreatic insufficiency (EPI), associated with chronic pancreatitis (CP) and cystic fibrosis (CF). AZX1101 is a recombinant-lactamase combination of bacterial origin under development for the prevention of hospital-acquired infections by resistant bacterial strains induced by parenteral administration of b-lactam antibiotics (known as nosocomial infections), as well as the prevention of antibiotic-associated diarrhea (AAD).
Tue, 21 Sep 2021
AzurRx BioPharma to Change Corporate Name to First Wave BioPharma Today - GlobeNewswire
Mon, 13 Sep 2021
AzurRx BioPharma Announces Acquisition of First Wave Bio and its Proprietary Niclosamide Formulations Targeting ... - GlobeNewswire
Mon, 13 Sep 2021
AzurRx BioPharma To Acquire First Wave Bio For $229M - Yahoo Finance
Mon, 04 Jan 2021
AzurRx BioPharma Announces Exclusive Worldwide License Agreement with First Wave Bio for Use of Proprietary ... - GlobeNewswire
Mon, 21 Dec 2020
Citius Pharmaceuticals Inc. (NASDAQ:CTXR) Reports Study Results Showing Effectiveness of Mino-Lok in Eradicating ... - BP Journal
Mon, 21 Dec 2020
CNS Pharmaceuticals Inc (NASDAQ:CNSP) Receives IND Application for Berubicin From the US FDA to Treat ... - BP Journal
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
Exchange:
NASDAQ
|
|
Sector:
Healthcare
|
|
Industry:
Biotechnology
|
|
Shares Out | 0 (M) |
Shares Float | 0 (M) |
Held by Insiders | (%) |
Held by Institutions | (%) |
Shares Short | 0 (K) |
Shares Short P.Month | 0 (K) |
EPS | |
EPS Est Next Qtrly | |
EPS Est This Year | |
EPS Est Next Year | |
Book Value (p.s.) | |
Profit Margin | % |
Operating Margin | % |
Return on Assets (ttm) | % |
Return on Equity (ttm) | % |
Qtrly Rev. Growth | % |
Gross Profit (p.s.) | |
Sales Per Share | |
EBITDA (p.s.) | |
Qtrly Earnings Growth | % |
Operating Cash Flow | 0 (M) |
Levered Free Cash Flow | 0 (M) |
PE Ratio | |
PEG Ratio | |
Price to Book value | |
Price to Sales | |
Price to Cash Flow |
Dividend | |
Forward Dividend | |
Dividend Yield | 0% |
Dividend Pay Date | |
Ex-Dividend Date |